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Introduction {#sec1}
============

The maintenance of genome stability requires the complete and faithful duplication of DNA in every cell cycle. Yet several obstacles impede the progression of replication forks (RFs), and these must be removed to avoid stalling and increased chromosome instability. A significant barrier to RF progression is transcription. First identified in bacteria, collisions between RFs and transcription bubbles also represent a major obstacle for DNA synthesis in eukaryotes, leading to defects in chromosome maintenance and an increase in levels of recombination ([@bib44], [@bib33], [@bib34], [@bib53], [@bib41], [@bib30], [@bib60]). In order to complete the full duplication of the chromosomes, replisomes must therefore overcome transcriptional barriers, removing both the DNA-bound RNA polymerase subunits and any DNA:RNA hybrids formed during transcription. These hybrids, usually limited to eight base pairs, occur naturally during RNA transcription and are typically removed when the RNA polymerase is disengaged from the DNA ([@bib1], [@bib64]).

At specific chromosomal loci, extended DNA:RNA hybrids can also form behind the site of RNA synthesis, through the re-annealing of nascent RNA to the template DNA and the displacement of the non-template DNA. These structures, named R-loops, form preferentially at highly transcribed genes with a high GC skew and can extend up to 1 kb in higher eukaryotes ([@bib1], [@bib56]). Formation of R-loops is favored by head-on collisions between RFs and actively transcribing complexes ([@bib30], [@bib42]), and their non-physiological accumulation, coupled to chromatin modification, is deleterious for genome stability ([@bib25]). Several pathways minimize the formation and stability of R-loops. For instance, the promotion of transcription processivity ([@bib32]), transcription termination ([@bib40], [@bib45]), timely processing, export or degradation of nascent mRNA ([@bib36], [@bib50]), or preventing torsional stress that arises during transcription ([@bib21], [@bib22]) all minimize R-loops' levels. Nevertheless, once formed, R-loops must be removed. A key role in R-loop removal is fulfilled by the RNase H enzymes that specifically digest RNA molecules within DNA:RNA hybrids ([@bib10]). In addition, several helicases can unwind DNA:RNA hybrids *in vitro*, including Sgs1 ([@bib12]) and Pif1 ([@bib6]). One such helicase, Sen1, is believed to play an essential role in the removal of R-loops from the DNA in yeast ([@bib47]).

Sen1 is an Upf1-like helicase that plays a key role in transcription termination ([@bib37], [@bib57], [@bib61], [@bib51]). Sen1 binds to the free 5′ ends of either RNA or DNA substrates and unwind both double-stranded DNA (dsDNA) and DNA:RNA hybrids ([@bib31], [@bib43], [@bib46], [@bib51]). *In vitro* analysis shows that Sen1 has high activity but limited processivity on DNA:RNA hybrid substrates ([@bib31]). Mechanistically, when Sen1 engages with nascent RNA exiting from a stalled RNA polymerase II (RNAPII), the helicase seemingly exerts a force on the polymerase to "push" it, either overcoming the stalling of RNAPII or disengaging it from the template DNA ([@bib51], [@bib31]). *In vivo* data also suggest that Sen1 is capable of removing RNAPII from the DNA it is bound to, thus terminating transcription ([@bib57], [@bib55], [@bib32]). In fact, a mutation in the catalytic domain of Sen1 (*sen1-1*) confers defects in transcription termination at non-permissive temperatures, leading to extensive readthrough of several transcription units ([@bib57]), accumulation of R-loops, and increased recombination ([@bib47]). Because of these defects, the viability of *sen1-1* cells depends on several repair factors ([@bib47], [@bib2]). Moreover, depletion of Sen1 leads to slow DNA replication and the accumulation of abnormal structures on 2D gels ([@bib2], [@bib7]).

Given its relatively low abundance and processivity ([@bib48], [@bib31]), Sen1 needs to be recruited at, or close to, sites where it can enact its biological function. Sen1 is recruited to the termination sites of cryptic-unstable transcripts (CUTs) and small nucleolar RNAs (snoRNAs) by binding to Nab3 and Nrd1, which both dock onto nascent RNA ([@bib3], [@bib52], [@bib17]). Nrd1 also interacts with Rpo21^Rpb1^ (the largest subunit of RNAPII) early in the transcription cycle ([@bib62]), thus restricting Sen1-dependent termination to short transcription units ([@bib29]). Sen1 also promotes termination of some genes downstream of the polyadenylation site, acting with Rat1 ([@bib47], [@bib54]), possibly by directly binding Rpo21 via its N-terminal domain ([@bib15]). Finally, it is likely that Sen1 is recruited at other genomic sites in a transcription-independent fashion. The human ortholog of Sen1 (Senataxin) co-localizes with 53BP1 to sites of DNA damage in a checkpoint-dependent manner ([@bib66]). Moreover, in *S. cerevisiae*, Sen1 co-localizes with replisome components and sites of bromodeoxyuridine (BrdU) incorporation ([@bib2]). However, the mechanism through which Sen1 is recruited at RFs has yet to be described. The significance of recruiting Sen1 to RFs is also poorly understood, as it has been impossible thus far to determine whether the defects in DNA replication upon inactivation of Sen1 are an indirect consequence of deregulated transcription termination, of a failure in R-loop removal, or the direct result of an important function of Sen1 at RFs. Here, we show that Sen1 binds the replisome during S phase through its N-terminal domain, map its binding site, generate a mutant that breaks this interaction, and explore the consequences of the loss of the helicase from RFs on chromosome stability.

Results {#sec2}
=======

Sen1 Interacts with the Replisome via Its N-Terminal Domain {#sec2.1}
-----------------------------------------------------------

The replisome is a complex and dynamic machine that relies on multiple interactions between its constituent proteins ([@bib4], [@bib8]). As part of a mass spectrometry (MS) screen to identify factors transiently or weakly associated to the core replisome, we observed that Sen1 co-purifies with the CMG helicase in *S. cerevisiae* ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To verify the MS data, we immunoprecipitated (IPed) Sen1 from extracts of yeast cells synchronized in G1, S, and G2. We observed that Sen1 interacted with replisome components only in S phase ([Figure 1](#fig1){ref-type="fig"}A). Immunoprecipitation (IP) of the GINS component Sld5 corroborated this observation ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Sen1 interacts with replisomes independently of either Nrd1 or Nab3 ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D) and independently of ongoing transcription ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F), as previously observed ([@bib2]). To further explore this interaction and its biological function, we mapped the interaction sites both in the replisome and Sen1.Figure 1Sen1 Interacts with the Replisome during S Phase through Its N-Terminal Domain(A) *SEN1* or *SEN1-TAP* cells were arrested in G1, harvested immediately, or released for either 30 min (S phase) or 60 min (G2 phase). Cell extracts and IP material were analyzed by immunoblotting (IB).(B) Schematic of Sen1 constructs used.(C) TAP-tagged fragments of Sen1, IPed from cells in S phase, were analyzed by IB.(D) TAP-tagged fragments of Sen1 were analysed as above, except 4× cells were used for the IP of the fragments containing the last 330 C-terminal amino acids.

Sen1 contains an extended N-terminal domain and an essential and conserved helicase domain ([@bib43]). To identify a region of Sen1 that is sufficient for binding replisomes, we generated TAP-tagged constructs of Sen1, expressed under an inducible *GAL1* promoter ([Figure 1](#fig1){ref-type="fig"}B). All fragments containing the helicase domain folded correctly and rescued *sen1-1* lethality at non-permissive temperatures, despite constructs containing the last 330 amino acids of the protein being highly labile ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). We then assessed the ability of the various fragments to interact with the replisome and observed that the N-terminal domain (residues 2--931) of Sen1 was both sufficient and necessary for association with replisomes ([Figures 1](#fig1){ref-type="fig"}C and 1D). Similarly, Sen1 (2--931) co-precipitated specifically with replisomes isolated from S phase cells by IP of Mcm3 (a subunit of the CMG helicase) ([Figures S1](#mmc1){ref-type="supplementary-material"}I and S1J). Thus, Sen1 (2--931) contains an interaction site for replisome components.

Sen1 Binding to the Replisome Depends on Ctf4 and Mrc1 {#sec2.2}
------------------------------------------------------

To identify specific proteins to which Sen1 binds within the replisome, we compared the G1 and S phase interactome of Sen1 (2--931) via MS analysis. As expected, Sen1 (2--931) IPed with replisomes in S phase ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, Ctf4 and GINS co-purified with the bait in G1 as well. This was confirmed by immunoblotting ([Figures 2](#fig2){ref-type="fig"}B and 2C). Because Ctf4 and GINS interacts throughout the cell cycle ([@bib23]), we next analyzed whether Sen1 binds preferentially to one of the components. The interaction between Ctf4 and Sen1 in G1 was unaffected by inactivating GINS via the *psf1-1* allele ([Figure 2](#fig2){ref-type="fig"}B; [@bib58]), but GINS no longer IPed with Sen1 (2--931) in G1 in the absence of Ctf4 ([Figure 2](#fig2){ref-type="fig"}C). These data indicate that Sen1 (2--931) binds to Ctf4 in the absence of other replisome components.Figure 2Sen1 Binds the Replisome Components Ctf4 and Mrc1(A) MS analysis of the proteins co-purifying with Sen1 (2--931) was conducted in S and G1 phases.(B) IB analysis of the proteins IPed with Sen1 (2--931) and an empty control in strains carrying the *PSF1* or *psf1-1* allele. Cells were arrested in G1, shifted to 37°C for 1 h (G1), and then released into S phase for 20 min at 37°C (S).(C) Sen1 (2--931) binding of GINS in G1 depends on Ctf4. IB analysis of the proteins IPed with Sen1 (2--931) and an empty control, with or without *CTF4*. Cells were arrested in G1 and released in S phase for 20 min at 30°C. Ctf4 and TAP-Sen1 (2--931) have similar sizes and run closely in gel electrophoresis.(D) IB analysis of the proteins interacting with TAP-Sen1 (2--931) in the presence or absence of origin firing and *CTF4*. Cells were treated as described in [Figure S2](#mmc1){ref-type="supplementary-material"}B. G1 samples were collected before galactose induction.(E) Wild-type, *mrc1Δ*, or *ctf4Δ* cells expressing TAP-Sen1 (2--931) were arrested in G1. IB analysis of cell extracts and IPs is shown.(F) Wild-type, *ctf4Δ*, *mrc1Δ*, and *ctf4Δ mrc1-AID* strains were arrested in G1, treated for 1 h with 0.5 mM auxin indole-3-acetic acid (IAA) final concentration, and released in S phase. IB analysis of cell extracts and IPs is shown.(G) Quantification of the relative signal of Sen1-9MYC versus the TAP-Sld5 signal, normalized against the wild type.(H) Experiments were conducted as in (F). Wild-type, *ctf4Δ*, and *ctf4Δ mrc1-AID* strains, carrying an untagged or a *SEN1-TAP* allele, were used. Asterisk indicates a non-specific band.

Interestingly, Sen1 (2--931) retained some affinity to the replisome in the absence of Ctf4 ([Figure 2](#fig2){ref-type="fig"}C, right panel), independently of DNA ([Figure S2](#mmc1){ref-type="supplementary-material"}A). This suggests that Sen1 interacts with at least another subunit of the replisome. To screen for such factors, we analyzed whether any component of the replisome binds to Sen1 (2--931) in cells progressing into S phase in the absence of origin firing. We used *td-sld3-7* cells that cannot initiate chromosome replication at 37°C following inactivation and degradation of td-Sld3-7 ([@bib38], [@bib39]; [Figure S2](#mmc1){ref-type="supplementary-material"}B). In control cells, Sen1 (2--931) co-purified with all tested replisome components in S phase ([Figure 2](#fig2){ref-type="fig"}D). In *td-sld3-7* cells, Sen1 IPed predominantly with Ctf4 and GINS but also weakly with the replisome component Mrc1. Strikingly, Sen1 (2--931)'s affinity for Mrc1 increased in a td-*sld3-7 ctf4Δ* background. We confirmed this in cells arrested in G1 as well ([Figure 2](#fig2){ref-type="fig"}E). These observations suggest that both Ctf4 and Mrc1 are binding partners of Sen1 in the replisome. Deletion of either replisome component leads to a decrease in replisome association to Sen1, even following crosslinking to capture weak interactions ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Because *ctf4Δ mrc1Δ* cells are inviable ([@bib23]), we generated a *ctf4Δ mrc1-AID* strain, with the auxin-degron fused to Mrc1 ([@bib49]) to allow rapid depletion of the protein. The association of Sen1 with the replisome was greatly reduced, although not entirely abolished, in cells with no Ctf4 and Mrc1 ([Figures 2](#fig2){ref-type="fig"}F--2H). These data indicate that, although other accessory binding partners might exist within the replisome, Sen1 mainly binds via Ctf4 and Mrc1.

*sen1-3* Fails to Bind the Replisome and Is Sensitive to Increased Levels of DNA:RNA Hybrids {#sec2.3}
--------------------------------------------------------------------------------------------

Deletion of the N-terminal domain of Sen1 causes pronounced defects in cell growth ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Thus, to investigate the role of Sen1 at RFs, we sought to generate a separation of function allele that is specifically defective for binding to replisomes. By generating truncations of the N-terminal domain, we identified that Sen1 (410--931) was the fragment with the highest affinity for replisomes although Sen1 (622--931) was the smallest construct still able to bind ([Figures 3](#fig3){ref-type="fig"}A--3C). By comparison with yeast orthologs of Sen1 ([Figure S3](#mmc1){ref-type="supplementary-material"}B), we identified conserved residues within this region and targeted them for mutagenesis, creating hemagglutinin (HA)-tagged alleles of *SEN1* that were expressed under the strong *ACT1* promoter in *sen1Δ* cells. All the tested mutations supported cell growth, but one allele, combining mutations W773A E774A W777A (henceforth referred to as *sen1-3*) was uniquely defective for interaction with replisomes ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C). Similar results were obtained when the *sen1-3* mutation was introduced at the endogenous *SEN1* locus ([Figures 3](#fig3){ref-type="fig"}E and 3F), even following crosslinking ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Importantly, Sen1-3 retained wild-type affinity for RNAPII (Rpo21). Hence, *sen1-3* is an allele that abrogates the interaction between Sen1 and replisomes.Figure 3Sen1-3 Does Not Interact with the Replisome(A) Summary of the ability of N-terminal fragments of Sen1 to interact with the replisome.(B) Cells carrying different *GAL1-3HA-SEN1* fragments and a *TAP-MCM3* allele were arrested in G1 and released into S phase. The samples were then used for IPs.(C) Sen1 fragments were analysed as in (B).(D) Cells carrying *ACT1-3HA-SEN1* wild-type or mutated alleles at an ectopic locus were synchronously released into S phase. IB analysis of cell extracts and IPs is shown.(E) Cells carrying a *SEN1*, *SEN1-TAP*, or *sen1-3-TAP* allele were arrested in G1 and released into S phase. IB analysis of cell extracts and IPs is shown.(F) Fluorescence-activated cell sorting (FACS) samples for the experiment in (E).

Next, we assessed whether the *sen1-3* mutation affects transcription termination, similarly to *sen1-1* cells ([@bib47]). We assayed the efficiency of termination at two model Nrd1-Nab3-Sen1 target genes, coding for a snoRNA (*SNR13*) and a CUT (*NEL025c*) ([@bib59], [@bib61]). Because termination defects lead to longer RNAs that can be targeted by the nonsense-mediated decay, strains lacking *UPF1* were also tested ([@bib18]). Cells with the *sen1-3* allele presented no defects in transcription termination, unlike *sen1-1* at 37°C ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}E). Defects in transcription termination were also analyzed genome-wide by mapping the distribution of RNAPII via the sequencing of nascent RNAs using CRAC (crosslinking and analysis of cDNAs) ([@bib27], [@bib9]). Metagene analysis using a set of validated CUTs ([Table S1](#mmc2){ref-type="supplementary-material"}) shows very similar RNAPII profiles between *SEN1* and *sen1-3* cells, although a clear general termination defect is observed upon depletion of Nrd1 ([Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}F). These data indicate that *sen1-3* is proficient in terminating RNAPII transcription.Figure 4The *sen1-3* Allele Is Proficient in RNAPII Termination but Is Essential in the Absence of RNase H Activity(A) *sen1-3* cells are proficient for transcription termination. qRT-PCR analysis of RNAs derived from the strains indicated is shown. The ratio of the readthrough fraction (position RT) over the total amount of *SNR13* RNA is shown (triplicate biological repeats). n.s., not significant.(B) Metagene analysis of RNAPII density detected by CRAC on CUTs. Average read counts are plotted on regions aligned to both the transcription start site (TSS) (left) and the transcript end site (TES) (right) of the CUTs (reads count in [Table S1](#mmc2){ref-type="supplementary-material"}). The profiles of RNAPII density following Nrd1 depletion (*nrd1-AID* + auxin) are included for comparison (dataset from [@bib9]). *nrd1-AID* strain behaves as a hypomorphic allele.(C) Examples of the meiotic progeny of the indicated diploids strains are shown.(D) Serial dilution spotting of the indicated strains is shown. *rnh1Δ rnh201Δ* is abbreviated as *rnhΔΔ.*(E) Serial dilution spotting of the indicated strains is shown. Cells (+*RNH1*) carry *GAL-RNH1* inserted ectopically.(F) The indicated strains, carrying a *RAD52-GFP* allele with or without the *GAL-RNH1* construct, were grown as shown in [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D. Samples were taken at the indicated time points, fixed, and analyzed for the presence of Rad52 foci (triplicate biological repeats). n.s., not significant; ^∗∗^p \< 0.05; ^∗∗∗^p \< 0.01.(G) The indicated strains were grown to exponential phase at 28°C; DNA:RNA hybrids were analyzed by immunofluorescence of chromosome spreads (triplicate biological repeats). Samples were treated in parallel with RNase H.

We then analyzed how the loss of Sen1 from replisomes affects cells. *SEN1* and *sen1-3* cells displayed comparable cell growth kinetics and sensitivity to both hydroxyurea (HU) and methyl methanesulfonate (MMS). One possibility might be that Sen1 at RFs is redundant with the enzymatic activity of other factors, such as the RNase H1 and H2 enzymes. We crossed *rnh1Δ rnh201Δ* cells with *SEN1 or sen1-3* strains and analyzed their meiotic progeny. Although single deletion of either *RNH1* or *RNH201* combined with *sen1-3* did not present any synthetic defects, *sen1-3 rnh1Δ rnh201Δ* cells were inviable ([Figure 4](#fig4){ref-type="fig"}C), similarly to *rnh1Δ rnh201*Δ *sen1-1* mutants ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Overexpression of *sen1-3* under the strong *ACT1* promoter suppresses the synthetic lethality of *sen1-3* with *rnh1Δ rnh201*Δ, suggesting that higher levels of Sen1 activity can compensate for lack of the specific replisome-tethering mechanism. Yet these cells display growth defects at 37°C, with cells accumulating in G2/M and triggering checkpoint activation ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3J). Moreover, *ACT1-sen1-3* is unable to suppress the hyper-sensitivity of *rnh1Δ rnh201Δ* to HU and is synthetic defective for MMS sensitivity ([Figure 4](#fig4){ref-type="fig"}D). Altogether, these findings suggest that Sen1 at RF might either be redundant with RNases H1 and H2 or become essential to deal with the DNA:RNA hybrids accumulating in the absence of RNase H.

To explore whether increased levels of DNA:RNA hybrids lead to synthetic defects in *sen1-3* cells, we generated *hpr1Δ sen1-3* cells. Hpr1 is a component of the THO complex involved in the processing and export of mRNA ([@bib14]). *hpr1Δ* mutants accumulate R-loops and show defects in transcription elongation ([@bib24], [@bib13], [@bib14]). *hpr1Δ sen1-3* double mutants showed growth defects at higher temperatures and increased sensitivity to replication stress ([Figure 4](#fig4){ref-type="fig"}E). To explore whether defects arise during DNA replication, we analyzed the kinetics of Rad52 foci formation in cells released in S phase. The experiment was conducted at permissive temperatures (28°C) as *hpr1Δ* cells failed to synchronously bud at 35°C and 37°C. We observed that *sen1-3* causes a small but statistically significant increase in recombination in late S phase, although *hpr1Δ sen1-3* cells showed synthetic defects and an increase in recombination ([Figures 4](#fig4){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}A--S4D). Interestingly, the increased rates of recombination and growth defects in *hpr1Δ sen1-3* cells were suppressed by overexpression of *RNH1* ([Figures 4](#fig4){ref-type="fig"}E and 4F), thus suggesting that DNA:RNA hybrids are toxic in these mutants.

To directly test the levels of DNA:RNA hybrids, we visualized them in chromosome spreads ([@bib63]). As previously observed, both *rnh1Δ rnh201Δ* and *hpr1Δ* mutants showed high levels of DNA:RNA hybrids ([Figures 4](#fig4){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}E; [@bib11]). Surprisingly, we did not observe any increase in the levels of DNA:RNA hybrids in *hpr1Δ sen1-3* cells. Similar results were observed by slot-blot analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Given that phenotypic suppression by RNase H overexpression is accepted as a marker for R-loops, these results suggest that the suppression of *hpr1Δ sen1-3* by overexpression of *RNH1* might occur by removing short or labile DNA:RNA hybrids, not readily detectable by the S9.6 antibody used in our analysis.

*sen1-3* Cells Are Defective in Replication Fork Progression and Genome Stability in the Absence of *MRC1* {#sec2.4}
----------------------------------------------------------------------------------------------------------

Because both *sen1-1* and *sen1-3* are synthetically lethal in the absence of *RNH1* and *RNH201*, we wanted to explore whether other pathways, essential for maintaining cell viability in *sen1-1* ([@bib2], [@bib47]), are also important in *sen1-3*. Only a subset of deletion mutants described to negatively affect viability in *sen1-1* cells showed robust defects in cell viability in *sen1-3* cells (summarized in [Figure 5](#fig5){ref-type="fig"}A). Namely, we observed temperature sensitivity and increased sensitivity to DNA-damaging agents when *sen1-3* was crossed with either *mrc1Δ*, *ctf18Δ*, or *rad53Δ sml1Δ* ([Figure 5](#fig5){ref-type="fig"}B).Figure 5*sen1-3* Presents Synthetic Defects with *mrc1Δ*, *ctf18Δ*, and *rad53Δ*, Leading to Increased Recombination and Mini-chromosome Loss(A) Summary of the genetic interactions tested with the *sen1-3* allele. Some double mutants (orange line) showed marked differences in temperature sensitivity and DNA damage sensitivity although others did not (green line).(B) Examples of the defects observed with *sen1-3.* Serial dilution spotting of the indicated strains is shown. The double mutant *rad53Δ sml1Δ* is indicated as *rad53Δ*.(C) The indicated strains were arrested in G1, shifted to 37°C for 1 h, and released in S phase at 37°C. FACS samples were taken at the indicated times. Red bar, length of DNA replication; green arrow, beginning of the end of mitosis.(D) Cells, carrying a *RAD52-GFP* allele, were treated as in (C). Samples were taken at the indicated time points, fixed, and analyzed for the presence of Rad52 foci (triplicate biological repeats). ^∗∗^p \< 0.05; ^∗∗∗^p \< 0.01.(E) Examples of the microscopy data of the experiment in (D). Scale bars represent 5 μm.(F) Serial dilution spotting of the indicated strains is shown. Cells (+*RNH1*) carry an ectopic *GAL1-RNH1* construct.(G) *RNH1* overexpression does not suppress the increase in recombination in *mrc1Δ sen1-3* cells. Cell cultures were treated as in (C), except they were grown in YPGAL medium (triplicate biological repeats). ^∗∗^p \< 0.05; ^∗∗∗^p \< 0.01.(H) The *sen1-3* allele causes an increase in recombination. The cells were transformed with the plasmids pL or pLYΔNS. The ratio of the number of the colonies carrying a recombinant plasmid (*LEU2*) over the total number of cells carrying a plasmid (*URA3*) is shown.(I) Cells were transformed with plasmids carrying an *ADE2* marker and 1 or 2 origins. Percentage of white colonies over the total number of colonies scored is shown (a measure of genome stability; ^∗∗∗^p \< 0.5 10^−7^).

Mrc1, Ctf18, and Rad53 are key components of the S phase checkpoint, and all three mutants confer temperature sensitivity in *sen1-3* cells. To further explore the defects of *mrc1Δ sen1-3* mutants, we analyzed the DNA replication dynamics of cells arrested in G1 and then released in S phase at 37°C. The *mrc1Δ sen1-3* cells show a delay during DNA replication and accumulation of cells arrested in G2/M ([Figure 5](#fig5){ref-type="fig"}C). Correspondingly, we observed an increase in Rad52-GFP foci accumulating during the later stages of DNA replication, both in the *mrc1Δ sen1-3* and *ctf18Δ sen1-3* cells released in S phase at 37°C ([Figures 5](#fig5){ref-type="fig"}D and 5E). In addition, *mrc1Δ sen1-3* and *ctf18Δ sen1-3* cells showed an increase in cells carrying multiple foci of Rad52 ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Similar to what is seen in [Figure 4](#fig4){ref-type="fig"}F, we also observed a small but statistically significant increase in Rad52 foci in *sen1-3* mutants compared to wild-type. To determine whether DNA:RNA hybrids contribute to the phenotypes observed in *sen1-3 mrc1Δ*, we repeated the experiments following the overexpression of *RNH1.* This failed to suppress the growth defects and the increase in recombination during S phase ([Figures 5](#fig5){ref-type="fig"}F, 5G, and [S5](#mmc1){ref-type="supplementary-material"}B). Similar results were obtained when overexpressing the human ortholog of *RNH1* ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D; [@bib63], [@bib5]).

To analyze whether the increased recombination observed during replication in *sen1-3*, *mrc1Δ sen1-3*, and *hpr1Δ sen1-3* compared to *SEN1* leads to an increase in genomic instability, we measured the rate of direct-repeat recombination using plasmids carrying partially overlapping fragments of the *LEU2* gene separated by 39 or 3,900 nt (plasmids pL and pLYΔNS, respectively) ([@bib47], [@bib26]). We observed, as previously described, that recombination increased with the length of the transcript. Moreover, although *mrc1Δ sen1-3* showed a modest increase in recombination compared to *mrc1Δ* for both plasmids, *hpr1Δ sen1-3* showed greater increases in the rate of recombination ([Figure 5](#fig5){ref-type="fig"}H). Furthermore, we tested for defects in mini-chromosome maintenance by transforming a single-copy plasmid carrying an *ADE2* gene and scoring for the rate of plasmid loss in the absence of selective pressure by measuring the rate of white colonies (carrying the plasmid) and red (without the plasmid). Cells carrying the *sen1-3* allele showed higher levels of plasmid loss, exacerbated in the absence of *MRC1* and *HPR1* ([Figures 5](#fig5){ref-type="fig"}I and [S5](#mmc1){ref-type="supplementary-material"}E). Strikingly, *sen1-3 hpr1Δ* completely failed to retain the plasmid. The addition of a second origin of replication did not rescue the chromosome maintenance defects, and overexpression of *RNH1* only partially suppressed the defects in *hpr1Δ sen1-3* cells ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

Discussion {#sec3}
==========

Here, we have shown that Sen1 is a bona fide partner of the yeast replisome. The N-terminal domain mediates binding to replisomes, mainly via Ctf4 and Mrc1. Additional binding partners of Sen1 are likely because Sen1 shows some residual interaction with replisomes in the absence of Ctf4 and Mrc1. It is not yet clear whether multiple Sen1 molecules are recruited to RFs by independently binding separate subunits of the replisome with different affinities or whether multiple replisome components coordinately bind a single Sen1 to increase its strength of interaction. IPs of the N-terminal domain of Sen1 suggest a competition between Mrc1 and Ctf4 for Sen1 as Mrc1 binding increases in *ctf4Δ* cells ([Figures 2](#fig2){ref-type="fig"}D and 2E). This supports the multiple independent binding hypothesis. However, deletion of either *CTF4* or *MRC1* decreases overall binding of Sen1 to the replisome ([Figures 2](#fig2){ref-type="fig"}F, 2H, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D), compatible with a cooperative recruitment of Sen1. Interestingly, the mutation of three amino acids in *sen1-3* abolishes binding to both Ctf4 and Mrc1. Thus, the mutated residues either correspond to the direct interaction site for both Ctf4 and Mrc1 or they cause a change in conformation of a larger section of Sen1, thus affecting two distinct binding surfaces for Ctf4 and Mrc1. Both hypotheses are compelling, and further work is needed to determine which is correct.

The *sen1-3* allele is a separation of function mutant that breaks the interaction with the replisome without affecting the binding to RNAPII or transcription termination ([Figures 3](#fig3){ref-type="fig"}E, [4](#fig4){ref-type="fig"}A, and 4B). However, we cannot exclude that *sen1-3* might affect other Sen1 interactions beyond the replisome. In addition, minimal levels of interaction with replisomes might be retained in *sen1-*3 cells, thus weakening the severity of the phenotype observed. Nevertheless, this allele provides us with a tool to dissect the function of the helicase at RFs without affecting its catalytic activity and the bulk of its transcription functions.

It has been previously proposed (using the *sen1-1* allele or Sen1 depletion) that Sen1's presence at RFs is required to quickly remove the R-loops accumulating and interfering with RF progression ([@bib2], [@bib7], [@bib47]). In our experimental setting, however, loss of Sen1 from RFs did not show increases in DNA:RNA hybrids or dramatic defects in RF progression ([Figures 4](#fig4){ref-type="fig"}G and [5](#fig5){ref-type="fig"}C). In fact, the loss of Sen1 from the replisome only leads to modest defects (small increases in post-replicative recombination and instability of mini-chromosomes; [Figures 4](#fig4){ref-type="fig"}F, [5](#fig5){ref-type="fig"}D, and 5I). This suggests that when Sen1 is proficient in transcription termination, there might be enough redundancy at the RFs to deal with DNA:RNA hybrids. However, we observe lethality or severe growth defects when the *sen1-3* allele is present in genetic backgrounds with high endogenous levels of R-loops, such as *rnh1Δ rnh201Δ* and *hpr1Δ.* This supports the idea of an important role for Sen1 in dealing with DNA:RNA hybrids at RFs. Surprisingly, we do not observe an increase in DNA:RNA hybrids levels in *sen1-3* and in *hpr1Δ sen1-3* cells ([Figures 4](#fig4){ref-type="fig"}G, [S4](#mmc1){ref-type="supplementary-material"}E, and S4F). Moreover, although increased levels of R-loops have been described for *top1Δ* ([@bib21]), *pif1Δ* ([@bib6], [@bib60]), *sgs1Δ* ([@bib12]), or *mlp1Δ* ([@bib24]), these deletions do not show defects in cell viability or DNA damage sensitivity in combination with *sen1-3* ([Figure 5](#fig5){ref-type="fig"}A). This suggests that not all increases in R-loops might be necessarily toxic in *sen1-3* cells. One possibility is that different mutations might lead to dissimilar levels or distinct biochemical features of the R-loops. Moreover, different genetic backgrounds might lead to the accumulation of DNA:RNA hybrids at different sites of the genome (as recently observed; [@bib16]). Therefore, Sen1 association with the replisome might become critical for the timely resolution of some DNA:RNA hybrids in specific circumstances.

The recruitment of Sen1 at RFs also appears to promote DNA replication independently of R-loops. In fact, in *sen1-3* cells, overexpression of *RNH1* fails to suppress the higher levels of recombination observed in *sen1-3* ([Figures 4](#fig4){ref-type="fig"}F and [5](#fig5){ref-type="fig"}D). Given the prominent role of Sen1 in transcription termination described in the literature, it is tempting to speculate that Sen1 might remove transcribing or stalled RNA polymerases at RFs ([@bib31], [@bib51]). Alternatively, Sen1 might be required to remove other barriers to fork progression, or *RNH1* overexpression might not be sufficient to remove DNA:RNA hybrids present at RF with kinetics similar to Sen1, thus leading to increased fork stalling. In either case, we observe that cells rely on the functions of Mrc1 to promote fork progression and minimize DNA recombination in a *sen1-3* background ([Figures 5](#fig5){ref-type="fig"}B--5G). Interestingly, we observe that three key mediators and effectors of the S phase checkpoint (*MRC1*, *CTF18*, and *RAD53*) genetically interact with *sen1-3*. We did not observe any synthetic defects between *sen1-3* and either *mec1Δ sml1Δ*, *tel1Δ*, or *mec1Δ sml1Δ tel1Δ* (not shown). This raises the possibility that Mrc1, Ctf18, and Rad53 might be involved in the response to defects arising in *sen1-3* cells independently of Mec1 and Tel1. Alternatively, the synthetic defects observed are the consequence of other deficiencies in these cells, independent of the S phase checkpoint response. For example, Mrc1 has a key role in RF progression ([@bib65], [@bib35], [@bib20]).

Given that eukaryotic orthologs of Sen1 contain an extended non-catalytic N-terminal sequence (the function of which is still largely unknown), it will be interesting to investigate further whether Senataxin or any of its paralogs (Aquarius, IGHMBP2, RENT1, and ZNFx1) associate with replisomes in higher eukaryotes.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse-HRPCell Signaling Technology\#7076; RRID:[AB_330924](nif-antibody:AB_330924){#interref55}Anti-sheep-HRPSigmaA3415; RRID:[AB_258076](nif-antibody:AB_258076){#interref60}Anti-Cdc45Labib LabN/AAnti-Csm3Labib LabN/AAnti-Ctf4Labib LabN/AAnti-Dpb2Labib LabN/AAnti-FLAGSigmaF3165; RRID:[AB_259529](nif-antibody:AB_259529){#interref65}Anti-HA (12CA5)Sigma11583816001; RRID:[AB_514505](nif-antibody:AB_514505){#interref70}Sheep IgGSigmaS1265; RRID:[AB_261431](nif-antibody:AB_261431){#interref75}Anti-Mcm3Labib LabN/AAnti-Mcm4Labib LabN/AAnti-Mcm5Labib LabN/AAnti-Mcm6Labib LabN/AAnti-Mrc1Labib LabN/AAnti-MYCSigmaM4439; RRID:[AB_439694](nif-antibody:AB_439694){#interref80}Anti-Nrd1Libri LabN/AAnti Nab3Libri LabN/AAnti-Psf1Labib LabN/AAnti-Pob3Labib LabN/AAnti-Pol1Labib LabN/AAnti-Pol2De Piccoli LabN/AAnti-Rad53Abcamab166859; RRID:[AB_2801547](nif-antibody:AB_2801547){#interref85}Anti-Rpo21Novus BiologicalsNB200-598SS; RRID:[AB_2252678](nif-antibody:AB_2252678){#interref90}Anti-Sld5K. LabibN/AAnti-TAP-HRPSigmaP1291; RRID:[AB_1079562](nif-antibody:AB_1079562){#interref95}Anti DNA:RNA hybrids S9.6KerafastENH001; RRID:[AB_2687463](nif-antibody:AB_2687463){#interref100}Cy3-conjucated anti-mouseJackson laboratories\#115165003; RRID:[AB_2338680](nif-antibody:AB_2338680){#interref105}Anti-dsDNAAbcamab27156; RRID:[AB_470907](nif-antibody:AB_470907){#interref110}**Chemicals, Peptides, and Recombinant Proteins**α-factorPepceuticalsN/AAcTEV proteaseThermo-Fischer12575015CalmodulinSigmaA6112Complete protease inhibitor cocktailRoche11 836 153 001DithiothreitolSigmaD0632DynabeadsInvitrogen14302DEthidium bromideSigmaE1510HydroxyureaSigmaH8627Methyl methanesulfonateSigma129925Propidium iodideSigmaP4864Protease Inhibitor CocktailSigmaP8215Sodium fluorideThermo-FischerS299500ZymolyaseZymo research\#E1005RNase HInvitrogen\#18021071Sodium glycerophosphateJohnson Matthey170096Universal NucleasePierce88700**Critical Commercial Assays**Amersham ECL Western Blotting Detection ReagentGE HealthcareRPN2108LightCycler® FastStart DNA Master SYBR Green IRoche03003230001MLV-Reverse TranscriptaseThermofischer28025013QuikChange Lightning Site-Directed Mutagenesis KitQIAGEN\#210519**Experimental Models: Organisms/Strains***S. cerevisiae* (from W303) CS1*MATa*Rothstein's labN/A*S. cerevisiae* (from W303) CS74*MATa pep4Δ*::*ADE2*Lab strainN/A*S. cerevisiae* (from W303) CS1125*MATa TAP-SLD5 (kanMX) SEN1-9MYC (hphNT) pep4Δ::URA3 ADE2*This studyN/A*S. cerevisiae* (from W303) CS1126*MATa SEN1-9MYC (hphNT) pep4Δ::URA3 ADE2*This studyN/A*S. cerevisiae* (from W303) CS1187*MATa TAP-SLD5 (kanMX) SEN1-9MYC (hphNT) pep4Δ::URA3 ADE2 ctf4Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS1353*MATa SEN1-TAP* (*kanMX*) *pep4Δ*::*ADE2*This studyN/A*S. cerevisiae* (from W303) CS1416*MATa TAP-MCM3 (kanMX) SEN1-9MYC (hphNT) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1711*MATa TAP-MCM3 (kanMX) GAL1-3HA-ø (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1714*MATa TAP-MCM3 (kanMX) leu2-3,112::GAL1-3HA-SEN1 (2-931) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1534*MATa TAP-SLD5 (kanMX) SEN1-9MYC (hphNT) pep4Δ::URA3 ADE2 mrc1Δ::hphNT*This studyN/A*S. cerevisiae* (from W303) CS1852*MATa leu2-3,112::GAL1-TAP-ø* (*LEU2*) *pep4Δ*::*ADE2*This studyN/A*S. cerevisiae* (from W303) CS1933*MATa leu2-3,112::GAL1-TAP-SEN1 (1095-2231)* (*LEU2*) *pep4Δ*::*ADE2*This studyN/A*S. cerevisiae* (from W303) CS1941*MATa leu2-3,112::GAL1-TAP-SEN1 (2-2231) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1942*MATa leu2-3,112::GAL1-TAP-SEN1 (2-1901) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1943*MATa leu2-3,112::GAL1-TAP-SEN1 (931-2231) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1956*MATa leu2-3,112::GAL1-TAP-SEN1 (2-1103) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS1957*MATa leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2030*MATa TAP-MCM3 (kanMX) leu2-3,112::GAL1-3HA-SEN1 (2-622) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2032*MATa TAP-MCM3 (kanMX) leu2-3,112::GAL1-3HA-SEN1 (410-931) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2056*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-ø (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2058*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2061*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-SEN1 (2-1901) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2062*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-SEN1 (1095-2231) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2148*MATa TAP-MCM3 (kanMX) leu2-3,112::GAL1-3HA-SEN1 (501-931) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2150*MATa TAP-MCM3 (kanMX) leu2-3,112::GAL1-3HA-SEN1 (622-931) (LEU2) pep4Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2184*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-SEN1 (2-1103) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2188*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-SEN1 (2-2231) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2451*MATα td-MYC-sen1-1 (klTRP1) GAL1-UBR1 (HISMX) leu2-3,112::GAL1-TAP-SEN1 (931-2231) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2458*MATa/MATα SEN1/SEN1 (931-2231) (HISMX)*This studyN/A*S. cerevisiae* (from W303) CS2582*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (931-2231) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2584*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2603*MATa leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2) pep4Δ::ADE2 ctf4Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS2607*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) W773A E774A W777A (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2609*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) D850A E851G V852A L853G L854A (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2611*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) V858A R859A I862A (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2615*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) D876G D877G V880G (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2617*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) V746G D747G P748G I749G (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2623*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) L656A S657A K658A I659A L660 (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2636*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) L656A S657A K658A I659A L660A (LEU2) NRD1- 9MYC (HIS3MX) pep4Δ:: ADE2 TAP-MCM3 (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2638*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2- 2231)W773A E774A W777A (LEU2) NRD1-9MYC (HIS3MX) pep4Δ:: ADE2 TAP-MCM3 (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2640*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2- 2231) D850A E851G V852A L853G L854A (LEU2) NRD1- 9MYC (HIS3MX) pep4Δ:: ADE2 TAP-MCM3 (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2642*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2- 2231) V746G D747G P748G I749G (LEU2) NRD1-9MYC (HIS3MX) pep4Δ:: ADE2 TAP-MCM3 (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2669*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) (LEU2) NRD1-9MYC (HIS3MX) pep4Δ:: ADE2 TAP-MCM3 (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2670*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2- 2231) (LEU2) NRD1-9MYC (HIS3MX) pep4Δ:: ADE2*This studyN/A*S. cerevisiae* (from W303) CS2716*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) D876G D877G V880G (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2718*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) T782G I783G Y784G (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS2734*MATa rnh1Δ:: hphNT rnh201Δ::HISMX*Lab strainN/A*S. cerevisiae* (from W303) CS2735*MATα rnh1Δ:: hphNT rnh201Δ::HISMX*Lab strainN/A*S. cerevisiae* (from W303) CS2791*MATa td-sld3-7 (kanMX) GAL1-UBR1 (HIS3MX) leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2+) pep4Δ:: ADE2*This studyN/A*S. cerevisiae* (from W303) CS2808*MATa SEN1-TAP (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2810*MATa sen1-3-TAP (kanMX)*This studyN/A*S. cerevisiae* (from W303) CS2853*MATa SEN1-TAP (kanMX) pep4Δ:: ADE2*This studyN/A*S. cerevisiae* (from W303) CS2854*MATa sen1-3-TAP (kanMX) pep4Δ:: ADE2*This studyN/A*S. cerevisiae* (from W303) CS2859*MATa SEN1-TAP (kanMX) pep4Δ:: URA3 mrc1Δ::hphNT*This studyN/AC *S. cerevisiae* (from W303) S2861*MATa sen1-3-TAP (kanMX) pep4Δ:: URA3 mrc1Δ::hphNT*This studyN/A*S. cerevisiae* (from W303) CS2903*MATa td-sld3-7 (kanMX) GAL1-UBR1 (HIS3MX) leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2) pep4Δ:: ADE2 ctf4Δ:: kanMX*This studyN/A*S. cerevisiae* (from W303) CS2938*MATα SEN1-TAP (kanMX) hpr1Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS2941*MATα sen1-3-TAP (kanMX) hpr1Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS2945*MATa SEN1-TAP (kanMX) sml1Δ::HISMX rad53Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2947*MATa sen1-3-TAP (kanMX) sml1Δ::HISMX rad53Δ::ADE2*This studyN/A*S. cerevisiae* (from W303) CS2955*MATa SEN1-TAP (kanMX) ctf18Δ::klTRP1*This studyN/A*S. cerevisiae* (from W303) CS2957*MATa sen1-3-TAP (kanMX) ctf18Δ::klTRP1*This studyN/A*S. cerevisiae* (from W303) CS3167*MATa leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2) pep4Δ::ADE2 psf1-1 (ts)*This studyN/A*S. cerevisiae* (from W303) CS3186*MATa leu2-3,112::GAL1-TAP-SEN1 (2-931) (LEU2) pep4Δ::ADE2 mrc1Δ::hphNT*This studyN/A*S. cerevisiae* (from W303) CS3321*MATα leu2-3,112::GAL1-RNH1 (2-348) (LEU2) SEN1-TAP (kanMX) mrc1Δ::hphNT*This studyN/A*S. cerevisiae* (from W303) CS3322*MATa leu2-3,112::GAL1-RNH1 (2-348) (LEU2) sen1-3-TAP (kanMX) mrc1Δ::hphNT*This studyN/A*S. cerevisiae* (from W303) CS3499*MATa SEN1-TAP* (*kanMX*) *pep4Δ*::*ADE2 ctf4Δ::kanMX mrc1-3IAA (HISMX) ADH1-OsTIR1 (klTRP1,URA3)*This studyN/A*S. cerevisiae* (from W303) CS3545*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-sen1-3 (2-2231) (LEU2) rnh1Δ:: hphNT rnh201Δ::HISMX*This studyN/A*S. cerevisiae* (from W303) CS3547*MATa sen1Δ::URA3-CP leu2-3,112::ACT1-3HA-SEN1 (2-2231) (LEU2) rnh1Δ:: hphNT rnh201Δ::HISMX*This studyN/A*S. cerevisiae* (from W303) CS3562*MATa SEN1-TAP* (*kanMX*) *pep4Δ*::*ADE2 ctf4Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS3662*MATa SEN1-TAP (kanMX) mrc1Δ::hphNT leu2-3,112::GAL1-RNH1 (2-348) (LEU2+)*This studyN/A*S. cerevisiae* (from W303) CS3664*MATa sen1-3-TAP (kanMX) mrc1Δ::hphNT leu2-3,112::GAL1-RNH1 (2-348) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS3702*MATa TAP-SLD5 (kanMX) SEN1-9MYC (hphNT) pep4Δ::URA3 ADE2 ctf4Δ::kanMX mrc1-3IAA (HISMX) ADH1-OsTIR1 (klTRP1,URA3)*This studyN/A*S. cerevisiae* (from W303) CS3731*MATα SEN1-TAP (kanMX) leu2-3,112::GAL1-RNH1 (2-348) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS3733*MATa sen1-3-TAP (kanMX) leu2-3,112::GAL1-RNH1 (2-348) (LEU2)*This studyN/A*S. cerevisiae* (from W303) CS3796*MATa SEN1-TAP (kanMX) mad2Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS3797*MATα sen1-3-TAP (kanMX) mad2Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS3903*MATa leu2-3,112::GAL1-RNH1 (2-348) (LEU2) SEN1-TAP (kanMX) hpr1Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS3905*MATa leu2-3,112::GAL1-RNH1 (2-348) (LEU2) sen1-3-TAP (kanMX) hpr1Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS4296*MATa SEN1-TAP (kanMX) chl1Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS4298*MATα sen1-3-TAP (kanMX) chl1Δ::kanMX*This studyN/A*S. cerevisiae* (from W303) CS4312*MATa NRD1-TAP (kanMX) SEN1-9MYC (hphNT) pep4Δ::URA3-CP ADE2*This studyN/A*S. cerevisiae* (from W303) CS4314*MATa SEN1-TAP (kanMX) pep4Δ::ADE2 rpb1-1 (ts)*This studyN/A*S. cerevisiae* (from W303) DLY2057*MATa sen1-1 (ts)*Lab strainN/A*S. cerevisiae* (from W303) DLY2281*MATa upf1Δ::TAP::klTRP1*Lab strainN/A*S. cerevisiae* (from W303) DLY3111*MATa sen1-1 (ts) upf1Δ::TAP::klTRP1*This studyN/A*S. cerevisiae* (from W303) DLY3190*MATa SEN1-TAP (kanMX) upf1Δ::TAP::klTRP1*This studyN/A*S. cerevisiae* (from W303) DLY3191*MATa sen1-3-TAP (kanMX) upf1Δ::TAP::klTRP1*This studyN/A**Oligonucleotides**DL377ATGTTCCCAGGTATTGCCGAThis studyN/ADL378ACACTTGTGGTGAACGATAGThis studyN/ADL474GCAAAGATCTGTATGAAAGGThis studyN/ADL475CGCAGAGTTCTTACCAAACGThis studyN/ADL481TAAATGGCCAACCGCTGTTGThis studyN/ADL482CCAGCGTACTGCACGCCAGGThis studyN/ADL1119AAGTGACGAAGTTCATGCTAThis studyN/ADL1120TCCGTGTCTCTTGTCCTGCAThis studyN/A**Recombinant DNA**pYM-N24[@bib68]EuroscarfpCS14pRS305-*GAL1-TAP-Ø*This studyN/ApCS25pRS305-*GAL1-3HA-Ø*This studyN/ApCS26pRS305-*GAL1-3HA-SEN1 (2-931)*This studyN/ApCS30pRS305-*GAL1-TAP-SEN1 (2-931)*This studyN/ApCS31pRS305-*GAL1-TAP-SEN1 (2-1103)*This studyN/ApCS32pRS305-*GAL1-TAP-SEN1 (931-2231)*This studyN/ApCS33pRS305-*GAL1-TAP-SEN1 (1095-2231)*This studyN/ApCS39pRS305-*GAL1-TAP-SEN1 (2-2231)*This studyN/ApCS40pRS305-*GAL1-TAP-SEN1 (2-1901)*This studyN/ApCS42pRS305-*GAL1-3HA-SEN1 (2-622)*This studyN/ApCS43pRS305-*GAL1-3HA-SEN1 (410-931)*This studyN/ApCS59pRS305-*GAL1-3HA-SEN1 (501-931)*This studyN/ApCS61pRS305-*GAL1-3HA-SEN1 (622-931)*This studyN/ApCS118pRS305-*ACT1-3HA-SEN1 (931-2231)*This studyN/ApCS120pRS305-*ACT1-3HA-SEN1 (2-2231)*This studyN/ApCS123pRS305-*ACT1-3HA-SEN1 (2-2231) W773A E774A W777A*This studyN/ApCS124pRS305-*ACT1-3HA-SEN1 (2-2231) L656A S657A K658A I659A L660A*This studyN/ApCS125pRS305-*ACT1-3HA-SEN1 (2-2231) D850A E851G V852A L853G L854A*This studyN/ApCS127pRS305-*ACT1-3HA-SEN1 (2-2231) D876G D877G V880G*This studyN/ApCS128pRS305-*ACT1-3HA-SEN1 (2-2231) V746G D747G P748G I749G*This studyN/ApCS129pRS305-*ACT1-3HA-SEN1 (2-2231) T782G I783G Y784G*This studyN/ApCS188pRS305-*GAL1-RNH1 (2-348)*This studyN/ApCS196pRS424-*GPD*-*hsRNASEH1* (2-286)From Palancade's labN/ApCS197pRS315-*ADE2*This studyN/ApCS198pRS315-*ADE2-ARS306*This studyN/ApLpRS316*-leu2Δ3′-39bp-leu2Δ5′*From Aguilera's labN/ApLYΔNSpRS316*-leu2Δ3′-3900bp-leu2Δ5′*From Aguilera's labN/A**Software and Algorithms**ExcelMicrosoftRRID:[SCR_016137](rridsoftware:SCR_016137){#intref0010}IllustratorAdobeRRID:[SCR_014198](rridsoftware:SCR_014198){#intref0015}ImageJNIH<https://imagej.nih.gov/ij/>; RRID:[SCR_003070](rridsoftware:SCR_003070){#intref0025}PhotoshopAdobeRRID:[SCR_014199](rridsoftware:SCR_014199){#intref0030}PredictProtein.org<https://www.predictprotein.org/>RStudioRStudioRRID:[SCR_000432](rridsoftware:SCR_000432){#intref0040}

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed and will be fulfilled by the Lead Contact, Dr Giacomo De Piccoli (<g.de-piccoli@warwick.ac.uk>). All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

*Saccharomyces cerevisiae* is the experimental model used in this study. All strains are isogenic to W303, and are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.

Method Details {#sec4.4}
--------------

### Yeast Strains and Growth Conditions {#sec4.4.1}

All yeasts were grown in YP medium supplemented with either glucose (YPD) or galactose (YPGAL) or raffinose (YPRAF) to a final concentration of 2% (w/v). For solid media, the same formulation was used, but with a final concentration of 1% (w/v) agar. Yeasts were grown at 24, 28, 30 and 37°C, depending on their viability at the different temperatures and as required by the experimental design. For all experiments, the control and test strains were subjected to the same conditions, including temperature.

For cell spotting experiments, cells were grown on non-selective media until colonies were judged to be sufficiently big. Five discrete colonies from individual strains were added to sterile deionised water to create a cell suspension. From this suspension, serial dilutions (0.5 x10^6^, 0.5 x10^5^, 0.5 x10^4^ and 0.5 x10^3^ cells/ml) were generated. 10 μL of each suspension was pipetted onto the appropriate media and grown for up to 5 days at the required temperatures.

To assess the genetic interaction between two or three genes, parents carrying the appropriate alleles were first crossed. Analysis of the meiotic progeny was conducted by inducing sporulation of the diploid strains in sporulation medium for 3-5 days at 24°C. Asci were treated with a 1:10 dilution of β-glucoronidase from *Helix pomatia* (Sigma) for 30 minutes, followed by tetrad dissection onto a YPD plate using a Singer MSM400 micromanipulator. Plates were incubated for 3-4 days at the appropriate temperature.

For the plasmid recombination assay, eight independent clones carrying the appropriate plasmid (pL or pLYΔNS) were each plated in medium lacking leucine (to select for recombination) or lacking uracil (marker for the presence of the plasmid) at 24°C. The experiment was repeated in triplicate. For plasmid loss assays, cells were transformed with the required plasmid (pCS197 or pCS198) and plated on minimum medium lacking leucine and incubated at 24°C. Colonies were left to grow until single isolated colonies were sufficiently big. Five to seven colonies for each strain were then picked, resuspended in sterile water and counted. Around 200-150 cells were then plated onto YPD and incubated at 24°C until red/white coloring was clearly visible. Cells were then incubated at 4°C for three days. We considered white and sectored colonies as white while only fully red colonies were scored as red. The experiment was repeated twice. The plasmid loss assay with or without *GAL-RNH1* was conducted in a similar manner, except that cells were grown and transformed in medium containing galactose and selected in medium lacking adenine (*LEU2* is the reporter gene for the *GAL1-RNH1* construct). Colonies were grown for longer periods of time before colonies were sufficient size big and were plated onto non-selective medium containing galactose.

### Cell cycle experiments {#sec4.4.2}

Cells were diluted from an inoculum to a density of 0.35 × 10^7^ cells/ml in a suitable volume and left to grow to a final density of 0.7 × 10^7^ cells/ml. The cells were then synchronized in G1 by adding α-factor to a final concentration of 7.5 μg/ml. After the first 90 min, α-factor was added every 30 min to a 3.25 μg/ml final concentration to maintain the cells in G1. When the cultures were shifted to 37°C, cells were spun down and resuspended in pre-warmed medium containing 7.5 μg/ml α-factor. Cells were released from the arrest by washing the cells twice with medium without α-factor. In all experiments in which cells were collected for IPs, cells were grown at 24°C and released into S phase for 30 min, unless stated otherwise in the figure legend. For expressing constructs under the *GAL1* promoter, strains were grown in YPRAF, arrested in G1 using α-factor, upon which YPGAL was substituted for YPRAF. Alternatively, YPGAL was used throughout the experiment (appropriate for constructs that were labile).

### Harvesting cells for IP {#sec4.4.3}

Harvested cells were immediately cooled to 4°C by washing with an ice-cold solution of HEPES-KOH (pH 7.9), followed by a wash in a solution of 100 mM HEPES-KOH (pH 7.9), 50 mM potassium acetate, 10 mM magnesium acetate and 2 mM EDTA-KOH, still at 4°C. After the wash, the solution was discarded and the cells were re-suspended in a fresh quantity of the same solution supplemented with protease and phosphatase inhibitors, so that the ratio of wet mass of the cells to the final mass of the suspension was either 1:4 (for 250 mL cultures) or 4:5 (for 1 l cultures). The re-suspended cells were immediately flash-frozen by pipetting into a flask holding liquid nitrogen. The frozen cells were kept at −80°C until use for IP. Before freezing, some cells were fixed in 70% (v/v) ethanol to test that cells did not progress through the cell cycle during sample preparation.

For cells with inducible constructs, cultures were grown as described above in YPRAF. After the cells were arrested in G1, the culture was substituted with YPGAL (supplemented with α-factor) to induce transcription from the *GAL1* promoter. Harvesting of G1 cultures can be performed prior to or after induction according to the experimental setup. After 35 min or 1 h of induction, the cells were released in S phase as described above and harvested either 30 min (24°C) or 20 min (30°C or 37°C) post-release. For temperature-sensitive strains or strains tagged with a temperature-degron (e.g *psf1-1*, *td-sld3-7* and *rnh1Δ rnh201Δ ACT1-sen1-3*), the strains were grown and synchronized in G1 at 24°C as described above. Once synchronized and, (optionally) constructs transcriptionally induced, the cells were shifted to 37°C for 1 h. α-factor was added every 20 min to maintain the cells in G1 to a final concentration of 7.5 μg/ml for 1 h. Synchronicity was monitored visually using a microscope and by harvesting a 1 mL sample of the culture by fixing in 70% (v/v) ethanol for flow-cytometric analysis. The cells were then washed and released in S phase. The cells were harvested 20 min after release, including for the *psf1-1* strains that do not actually undergo DNA replication at 37°C as the GINS complex is destabilized. For crosslinking IPs, cells cultures were incubated with formaldehyde for 25 min and treated as in [@bib19].

### Western Blots {#sec4.4.4}

Protein samples (TCA-precipitated and non-treated cell extracts, as well as IPs) were run on 5, 6, 7, 8 or 10% polyacrylamide gels. The protein bands were then transferred onto nitrocellulose or PVDF membranes. The proteins bands were then probed with the appropriate primary antibodies for 1 h in a solution of 5% (w/v) skimmed milk in TBST, washed thrice for 5 min in fresh TBST, probed with the appropriate HRP-bound secondary antibody (if any, refer to [Key Resources Table](#sec4.1){ref-type="sec"}) and washed thrice again for 5 min in fresh TBST. The membrane was then treated with the western blotting reagents and the resulting chemiluminescent signal was captured using either films or a digital camera (G:BOX, Chemi XRG, Syngene).

### IP {#sec4.4.5}

IPs were conducted as previously described ([@bib19]). In brief, cells previously harvested were lysed using a mechanised pestle and mortar at −80°C (Spex Sample Prep, 6870). 1 g of lysate is considered equivalent to 1 ml. To 1 volume of thawed lysate, ¼ volume of a solution of 50% (v/v) glycerol, 100 mM HEPES-KOH (pH 7.9), 50 mM potassium acetate, 50 mM magnesium acetate, 0.5% (v/v) Igepal® CA-630, 2mM EDTA supplemented with protease and phosphatase inhibitors was added. Pierce Universal Nuclease was added to a final concentration of 0.4 U/μl and samples were left on a rotating platform at 4°C for 30 min. After incubation, the sample was clarified by stepwise centrifugation at 18,700*g* and then at 126,600*g*. The supernatant was isolated, 50 μL of which was added to 100 μL of 1.5 x Laemmli buffer (cell extract). The remaining cell extract was incubated with 100 μL of TAP-beads for 2 h (M-270 Dynabeads® Epoxy beads bound to an anti-sheep IgG). Beads were washed with solutions of 100 mM HEPES-KOH (pH 7.9), 50 mM potassium acetate, 50 mM magnesium acetate, 2 mM EDTA, 0.1% (v/v) Igepal® CA-630 thrice. After washing, 100 μL of 1 x Laemmli buffer was added to the 100 μL of TAP-beads and boiled for 4 min. Crosslinking IPs were conducted as in [@bib19].

When scaling up was necessary (using 1 l of cells instead of 250 ml), a few changes were implemented to the protocol. Notably, the concentration of the Pierce Universal Nuclease was increased four-fold to a final concentration of 1.6 U/μl and incubation with the nuclease was increased from 30 to 40 min.

### MS Analysis of IPs {#sec4.4.6}

The samples were processed as above. Following the washes, TAP-Sen1 (2-931) protein was released by using the AcTEV® protease at 24°C for 2 h. Thereafter, the resultant CBP-Sen1 (2-931) (CBP: calmodulin-binding protein) and its specific interactors were incubated with pre-washed calmodulin beads at 4°C for 2 h. After washing, 30 μL of 1 X Laemmli was added to the calmodulin beads and boiled for 4 min. The samples from the four biological replicates were pooled together, flash-frozen on dry ice and stored at −80°C. The samples were then run on commercially sourced 4%--12% acrylamide gel for a short distance (∼1 cm). The gel was then cut in thin slices and processed and analyzed by MS Bioworks, USA.

### Counting of Rad52-foci to assess DNA damage {#sec4.4.7}

Cells carrying the *RAD52-GFP* allele were first grown in liquid medium and synchronized in G1. Cells were released and harvested at different times after release, corresponding to different phases of the cell cycle. Paraformaldehyde was added to the cell suspensions to a final concentration of 3% (w/v) and the samples were incubated at room temperature for 10 min. The cells were then washed with PBS at room temperature. Finally, the samples were re-suspended in fresh PBS and kept at 4°C overnight.

Less than 24 h after fixation (to minimize signal lost due to alteration of the GFP protein), the samples were re-suspended in 500 μL of fresh PBS to which the DNA stain DAPI was added to a final concentration of 1 μg/ml. The samples were incubated at room temperature for 10 min to allow for staining of the DNA. The cells were then washed with PBS to improve the signal-to-noise ratio of the DAPI staining. The cells were then brought to a suitable dilution prior to pipetting on a glass slide onto which a coverslip is applied. Images of cells were acquired (brightfield, ∼510 nm emission (GFP), ∼460 nm (DAPI)) using a Personal DeltaVision (Applied Precision). The images were analyzed using ImageJ and the number of Rad52-foci were counted. An average of three experiments is shown in the figures.

### Chromosome spreads and microscopy {#sec4.4.8}

Chromosome spreads were performed as previously described ([@bib63], [@bib28]). Exponentially growing asynchronous cultures were grown in YPD at 28°C. 2x10^8^ cells were harvested and spheroplasted (0.1M potassium phosphate (pH 7.4), 1.2 M sorbitol, 0.5 mM MgCl2, 40 mM DTT, 20 U zymolyase at 30°C for 1 h or until \> 90% of cells lysed following addition of 2% sarcosyl. Cells were then washed and resuspended in ice cold 1 M sorbitol (pH 6.4), 0.1 M MES, 0.5 mM MgCl2, 1 mM EDTA to stop spheroplasting reaction. 20 μL of cell suspension was placed onto a slide, followed by 40 μL of fixative (4% paraformaldehyde (w/v), 3.4% sucrose (w/v)), then lysed using 80 μL of 1% lipsol (v/v) for 2 min, followed by addition of 80 μL of fixative and spread across the surface of the slide to dry overnight. Slides pre-treated with RNase H were incubated with 4U of RNase H diluted in 400 μL of 5mg/ml BSA for 1 h at 37°C prior to immunostaining. Slides were immunostained for DNA:RNA hybrids using mouse monoclonal antibody S.96 (Kerafast) diluted 1:2000 (0.25 μg/ml) in blocking buffer (5% BSA, 0.2% milk, 1XPBS) for 1 h. The secondary antibody, Cy3-conjucated goat anti-mouse (Jackson laboratories) was diluted 1:2000 in blocking buffer and incubated in the dark for 1 h. Indirect immunofluorescence was observed using a Deltavision 1 microscope with a 100 × /NA 1.4 objective. Image analysis was performed using ImageJ and Adobe Photoshop. An average of three experiments is shown in the figures.

### Quantification of R-loops {#sec4.4.9}

Cells growing in liquid culture was harvested and re-suspended in lysis solution (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 3% (w/v) SDS). To a volume of cell suspension, an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) (Acros Organics) and another volume of nuclease-free deionised water were added. The cells were then lysed mechanically using glass beads and DNA was isolated by incubating the soluble cell extract to ethanol to a final concentration of 70% (v/v). The DNA was washed with fresh ethanol and re-suspended in nuclease-free TE supplemented with 50 μg/ml RNase A and incubated at 37°C for 1 h only.

The concentration of genomic material was estimated by measuring absorbance at 260 nm. For each sample, 1 μg/μl, 0.5 μg/μl and 0.25 μg/μl dilutions of DNA was prepared, using nuclease-free water. 2 μL of each dilution was treated with either 1U of RNaseH (Invitrogen, \#18021071) or 1 U of RNaseH and 1 U of RNase III (Invitrogen, \#AM2290) with similar results at 37°C for 1h. As a control, untreated samples were also incubated at 37°C for 1 h. The remaining DNA was then added to 200 μL of 2 X SSC hybridization buffer (0.3M NaCl, 30mM trisodium Citrate, pH 7.0) and transferred to a pre-equilibrated hybond-N+ nylon membrane (GE healthcare, \#RPN203B) under vacuum. The DNA was cross-linked to the membrane using UV prior to blocking in either 5% (w/v) milk (anti-R loops) or 5% (w/v) BSA (anti ds-DNA) at 24°C for 1 h. The membranes were then incubated overnight in 5% milk supplemented the primary antibody at 4°C overnight. After thrice washing in TBST for 30 min, the membrane was incubated with anti-mouse IgG-HRP at 24°C for 1 h. The membranes were treated with ECL, and chemiluminescent signal was visualized using a camera (G:BOX, Chemi XRG, Syngene).

### Reverse transcription followed by quantitative PCR {#sec4.4.10}

Cells were grown to exponential phase and incubated at permissive (24°C) or non-permissive temperatures (37°C) for 3 h to induce the *sen1-1* phenotype before collection. Analysis was performed in parallel in an *upf1Δ* background for detecting elongated RNA species derived from termination failure that might be degraded in the cytoplasm. The ratio of the read-through fraction over the total amount of *SNR13* RNA is shown as a proxy of transcription termination levels. The mean of three experiments is shown. Error bars represent the standard deviation. Cells were grown in logarithmic phase, and 6 OD~600~ worth of cells were pelleted. Total RNAs were extracted by resuspending cell pellets in 1 volume of acidic phenol (pH 4.3) supplemented with 1 volume of AES Buffer (50 mM Sodium Acetate pH 5.5, 10 mM EDTA, 1% SDS). Mixtures were incubated at 70°C with agitation (1,400 rpm) for 30 min in a thermomixer (Eppendorf), before being centrifuged at *20,000 g* at 4°C for 10 min. Aqueous phases were recovered and subjected to one extra round of hot acidic phenol extraction, followed by one round of chloroform extraction. Total RNAs were finally precipitated with absolute ethanol and sodium acetate pH 5.5, washed once with 70% Ethanol, dried on a SpeedVac (Thermo) and resuspended in 30 μL of RNase-free H~2~O. 60-120 μg of total RNAs were recovered routinely.

Reverse transcription was performed using random hexamer-primers annealing at multiple *loci* in the *S. cerevisiae* genome and with oligos dT. 4 μg of total RNAs were mixed to 200 ng of random hexamers and 0.5 μM of oligos dT in a 20 μL reaction containing 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2 and 5 mM DTT. Samples were first incubated for 15 min at 70°C to allow RNA denaturation. Then temperature was slowly decreased to 37°C to allow annealing of primers. Lastly, synthesis of cDNAs was performed by adding 200 units of MLV-reverse transcriptase for 45 min at 37°C.

To assess the amount of cDNAs reverse transcribed, quantitative PCR (qPCR) was carried out using two different primer pairs for each target (*SNR13, NEL250c, ACT1*). These allowed the amplification of a product covering either ∼300 bp of the 3′ end of *ACT1* (DL377/DL378 primer pair) or ∼70 bp in the read-through region of *SNR13* (DL1119/DL1120 primer pair) or ∼140 bp in the body of *NEL025c* (DL474/DL475 primer pair) or ∼70 bp in the read-though region of *NEL025c* (DL481/DL482 primer pair). qPCR was performed in a 10 μL reaction by mixing 2 μL of the reverse transcribed cDNAs to 5 μL of LightCycler® 480 SYBR Green I Master and 2.5 pmol of both the forward and the reverse primer.

### Cross-linking and analysis of cDNA (CRAC) {#sec4.4.11}

The CRAC protocol used in this study is derived from [@bib27] with a few modifications as described in [@bib9]. Raw data processing has been performed as described in [@bib9]. Metagene analysis has been performed as follows: for the CUTs presented in [Table S1](#mmc2){ref-type="supplementary-material"}, we retrieved the polymerase reads count at every position around the features (3′ or 5′ end) and plotted the mean over all the values for these positions in the final aggregate plot. Analysis has been performed in the R Studio environment.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Where applicable, data was presented as the average ± standard deviation. t tests were used to compare population means. Statistically significant differences were indicated as such by indicating the value range of the p values.

Data and Code Availability {#sec4.6}
--------------------------

The published article includes all datasets generated or analyzed during this study. The raw data of the metagene analysis of the CUTs shown in [Figure 4](#fig4){ref-type="fig"}B are included in [Table S1](#mmc2){ref-type="supplementary-material"}. This study did not generate any unique code.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5Table S1. Read Count Scores from RNAPII CRAC at CUTs, Related to Figure 4The reads count, at their position around the CUTs (3′ or 5′ end), are shown. These data were then used for the metagene analysis in the aggregate plot shown in Figure 4B.Document S2. Article plus Supplemental Information
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